Protease inhibitors

Patent metadata

Field	Value
Publication number	US-11312693-B2
Application number	US-202016940067-A
Country	US
Kind code	B2
Filing date	Jul 27, 2020
Priority date	Sep 24, 2008
Publication date	Apr 26, 2022
Grant date	Apr 26, 2022

Abstract

Compounds of the formula II:whereinR1 and R2 are independently H, F or CH3; orR1 forms an ethynyl bond and R2 is H or C3-C6 cycloalkyl which is optionally substituted with one or two substituents independently selected from methyl, CF3, OMe or halo;R3 is C1-C3 alkyl or C3-C6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy, when R3 is C3-C6 cycloalkyl it may alternatively be gem substituted with fluoro;R4 is methyl or fluoro; m is 0, 1 or 2;E is a bond, or thiazolyl, optionally substituted with methyl or fluoro;A1 is CH or N,A2 is CR6R7 or NR6, provided at least one of A1 and A2 comprises N;R6 is H, C1-C4 alkyl, C1-C4 haloalkyl, C1-C3 alkyl-O—C1-C3 alkyl, or when A2 is C, R6 can also be C1-C4 alkoxy or F;R7 is H, C1-C4 alkyl or For a pharmaceutically acceptable salt, N-oxide or hydrate thereof, have utility in the treatment of disorders characterized by inappropriate expression or activation of cathepsin K, such as osteoporosis, osteoarthritis, rheumatoid arthritis or bone metastases.

First claim

The invention claimed is:

1. A compound of the formula Ih′″:

wherein the depicted N-Boc is optionally replaced by a conventional N-protecting group selected from the group consisting of formyl, acetyl, benzoyl, pivaloyl, t-butylacetyl, phenylsulfonyl, benzyl, and benzoxycarbonyl, and/or the depicted dimethylacetal protecting group is optionally replaced by 1,3-dioxolane protecting group.

2. The compound according to claim 1 , consisting of the N-Boc and dimethylacetal protecting groups depicted in Formula Ih′″.

3. A method for the treatment of osteoarthritis, comprising the administration to a patient in need thereof a safe and effective amount of a compound of the formula II:

wherein:
A 1 is CH or N;
A 2 is CR 6 R 7 or NR 6 , provided at least one of A 1 and A 2 comprises N;
E is thiazolyl, optionally substituted with methyl or fluoro;
m is 0, 1 or 2;
n is 0 or 1, such that the ring containing A 1 and A 2 is a saturated, nitrogen-containing ring of 5 or 6 ring atoms;
R is H, methyl, CF 3 , OMe or halo, located at any of the 1, 2 or 3 positions on the depicted cyclopropyl in Formula II;
R 3 is C 1 -C 3 alkyl or C 3 -C 6 cycloalkyl, either of which is optionally substituted with one or two methyl and/or a fluoro, trifluoromethyl or methoxy;
R 4 is methyl or fluoro;
R 6 is H, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, C 1 -C 3 alkyl-O—C 1 -C 3 alkyl, or when A 2 is C, R 6 can also be C 1 -C 4 alkoxy or F;
R 7 is H, C 1 -C 4 alkyl or F;

or a pharmaceutically acceptable salt, N-oxide or hydrate thereof, to a subject in need thereof.

Assignees

• Medivir Ab

Inventors

• Oden Lourdes Salvador
• Nilsson Magnus
• Kahnberg Pia
• Samuelsson Bertil
• Grabowska Urszula

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61P25/04

  Centrally acting analgesics, e.g. opioids · CPC title

• A61P3/14

  for calcium homeostasis (vitamin D A61P3/02; parathyroid hormones A61P5/18; calcitonin A61P5/22; osteoporosis A61P19/10; bone metastasis A61P35/04) · CPC title

• C07D495/04

  Ortho-condensed systems · CPC title